Laverock Therapeutics raises £13.5m to accelerate gene silencing platform 02-Oct-2023 By Isabel Cameron Laverock Therapeutics, the gene editing-induced gene silencing platform for human therapeutic applications, has expanded its seed funding round to £13.5 million.
ReNAgade Therapeutics launches with $300M financing to unlock ‘limitless potential’ of RNA medicine 25-May-2023 By Isabel Cameron ReNAgade Therapeutics has announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.